Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS. Khan MM, et al. Among authors: califf rm. J Am Coll Cardiol. 1998 Jan;31(1):31-6. doi: 10.1016/s0735-1097(97)00423-3. J Am Coll Cardiol. 1998. PMID: 9426014 Free article. Clinical Trial.
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ. Ellis SG, et al. J Am Coll Cardiol. 1998 Nov 15;32(6):1619-23. doi: 10.1016/s0735-1097(98)00403-3. J Am Coll Cardiol. 1998. PMID: 9822087 Free article. Clinical Trial.
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Cho L, et al. J Am Coll Cardiol. 2000 Aug;36(2):381-6. doi: 10.1016/s0735-1097(00)00746-4. J Am Coll Cardiol. 2000. PMID: 10933346 Free article.
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Holmes DR Jr, et al. Among authors: califf rm. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p. J Am Coll Cardiol. 1995. PMID: 7642857 Free article. Clinical Trial.
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Lincoff AM, Topol EJ, Califf RM, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Ellis SG. Lincoff AM, et al. Among authors: califf rm. Am J Cardiol. 1995 May 1;75(14):871-6. doi: 10.1016/s0002-9149(99)80678-x. Am J Cardiol. 1995. PMID: 7732992 Clinical Trial.
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Moliterno DJ, et al. Among authors: califf rm. Am J Cardiol. 1995 Mar 15;75(8):559-62. doi: 10.1016/s0002-9149(99)80616-x. Am J Cardiol. 1995. PMID: 7887377 Clinical Trial.
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Kleiman NS, et al. Among authors: califf rm. J Am Coll Cardiol. 1993 Aug;22(2):381-9. doi: 10.1016/0735-1097(93)90041-x. J Am Coll Cardiol. 1993. PMID: 8335808 Free article. Clinical Trial.
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ. Lefkovits J, et al. Among authors: califf rm. Am J Cardiol. 1996 May 15;77(12):1045-51. doi: 10.1016/s0002-9149(96)00128-2. Am J Cardiol. 1996. PMID: 8644655 Clinical Trial.
Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Lefkovits J, et al. Among authors: califf rm. J Am Coll Cardiol. 1996 Oct;28(4):849-55. doi: 10.1016/s0735-1097(96)00239-2. J Am Coll Cardiol. 1996. PMID: 8837559 Free article. Clinical Trial.
1,333 results